Tumor infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple negative invasive breast Cancer

Triple-negative breast cancer (TNBC) has an aggressive behavior, limited therapeutic options, and high mortality rate. Neoadjuvant chemotherapy (NACT) is a standard treatment for TNBC and patients with pathological complete response (pCR) have a favorable outcome. We conducted a comprehensive evaluation of cancer clinicopathologic parameters, and correlated these parameters with the pCR rate and the overall survival. Fifty-eight patients with TNBC of no special type who underwent breast biopsy, neoadjuvant therapy, and mastectomy in our institution during 2005–2016 were included in this study.

https://ift.tt/2LmUALE